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Background: Diabetes mellitus is associated with many kinds of complications. Recent studies have shown that
oxidative stress and inflammatory reactions have critical roles in the pathogenesis of diabetic gastroparesis.
Curcumin is known to have antioxidant and anti-inflammatory properties. In the present study, we investigated the
effect of curcumin on diabetic gastric motility in a Sprague Dawley rat model of type 1 diabetes mellitus.
Methods: Male SD rats were divided into a control group, a control group receiving curcumin, a diabetic group,
and a diabetic group receiving curcumin. Diabetes was induced by intraperitoneal injection of streptozotocin.
Curcumin (150 mg/kg) was given intragastrically for 6 weeks, and blood glucose levels and body weights were
measured. Stomachs were excised for analysis of gastric emptying rates, and levels of oxidative stress. NF-κB, I-κB,
and stem cell factor (SCF)/c-kit protein levels were assessed by western blot analysis, while the apoptosis of
interstitial cells of Cajal (ICCs) was assessed by TUNEL staining.
Results: Curcumin-treated diabetic rats showed significantly improved gastric emptying rates [(59.4 ± 7.5)%]
compared with diabetic rats [(44.3 ± 5.7)%], as well as decreased levels of MDA [21.4 ± 1.8 (nmol/mg) vs 27.9 ± 2.1
(nmol/mg)], and increased SOD activity [126.2 ± 8.8 (units/mg) vs 107.9 ± 7.5 (units/mg)]. On the other hand, the
gastric emptying level in the control group was not significantly different from that in the control group receiving
curcumin treatment. In addition, curcumin-treated diabetic rats showed significantly increased levels of SCF/c-kit
protein in stomach tissues, inhibited I-κB degradation and NF-κB activation, and reduced ICC apoptosis index
[(26.2 ± 4.1)% vs (47.5 ± 6.2)%], compared with the diabetic group.
Conclusion: Curcumin treatment improved gastric emptying by blocking the production of oxidative stress,
abolishing NF-κB signal transduction and enhancing expression of SCF/c-kit in rats with diabetic gastroparesis.
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Diabetic gastroparesis is a disease of the digestive tract,
defined as delayed emptying of a solid meal, and is seen
in 30–50% of patients with type 1 or type 2 diabetes
mellitus [1]. Patients often present upper gastrointestinal
symptoms, such as early satiety, weight loss, abdominal
bloating, abdominal discomfort, nausea, vomiting occur* Correspondence: liuqianghare@163.com
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reproduction in any medium, provided the orfrequently, and impaired glycemic control, and the dis-
ease seriously affects patients’ quality of life.
Gastroparesis is increasingly being recognized as a sig-
nificant health problem. Although gastroparesis affects
many diabetics worldwide, not only are the treatment
options very limited, but also the treatments that are
available for diabetic gastropathy are frequently ineffect-
ive. These include medical therapy, gastric electrical
stimulation, surgical therapy, and nutritional support.
Medications for gastroparesis include metoclopramide,
domperidone, cisapride, and erythromycin. While theseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been reported to be of only limited efficacy, and
many patients cannot tolerate them because of their side
effects. In diabetic patients with refractory gastroparesis,
high-frequency gastric electrical stimulation by a per-
manently implanted system significantly improved upper
digestive tract symptoms and represents an alternative
surgical therapy for patients. Surgical procedures, such
as gastrectomy and antrectomy are the last option for
treatment, being controversial and in need of more study
[2]. In patients with severe gastroparesis but normal
small intestinal motility, jejunostomy tube feeding may
be applied. While this provides nutritional support, it
does not cure gastroparesis [3]. Diabetic gastroparesis is
generally best treated medically, and only patients with
severe diabetic gastroparesis who have failed to respond
to medical therapy should undergo other therapies.
Thus, finding drugs that show efficacy in treating dia-
betic gastroparesis is necessary.
Diabetic gastroparesis is associated with a loss of inter-
stitial cells of Cajal (ICCs) in both humans and model
animals [4]. ICCs can be identified in tissue by labeling
with antisera to the receptor tyrosine kinase kit, a pro-
tein expressed on ICCs. Kit and its ligand stem cell fac-
tor (SCF) are also important survival factors for ICCs
[5]. The increased oxidative stress associated with dia-
betes can lead to loss of or damage to ICCs in mice,
while oxidative stress leads to damage and loss of ICC
networks and the development of delayed gastric empty-
ing [6]. Diabetes results in increased oxidative stress and
has an important role in the pathogenesis of diabetic
complications [7]. Overproduction of reactive oxygen
species (ROS) results in oxidative damage, including
lipid peroxidation, protein oxidation, and DNA damage,
which can lead to cell death. Furthermore, ROS are
known to act as second messengers to activate transcrip-
tion factors such as nuclear factor kappa B (NF-κB).
ROS generated during stress in gastric tissue may trigger
the activation of the NF-κB signaling cascade; indeed,
gastric emptying in diabetic rats is associated with acti-
vation of NF-κB–mediated inflammation.
Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-
heptadiene-3,5-dione) is the main active component of
turmeric isolated from the plant curcuma longa L.
Curcumin is a multifunctional molecule with significant
regulatory effects on cancer [8], inflammation [9] and
diabetic-related diseases such as diabetic retinopathy
[10], diabetic nephropathy [11], and diabetes cognitive
dysfunction [12]. Curcumin is a potent scavenger of re-
active oxygen and nitrogen species such as hydroxyl
radicals and nitrogen dioxide radicals [13]. Several stud-
ies have demonstrated that curcumin inhibits activation
of NF-κB proinflammatory signaling pathways [14].
Meanwhile, NF-κB transcription factors regulate anumber of important physiological processes, including
inflammation and immune responses, cell growth and
survival, so inhibition of NF-κB signaling represents a vi-
able strategy for disease therapy [15]. However, there has
been very little research on the potential for curcumin to
treat diabetic gastroparesis, or on its pharmacological
mechanism.
The goal of this study was to determine whether, in
a Sprague Dawley (SD) rat model of type 1 diabetes
mellitus, middle-dose [16] curcumin could protect ICCs
in diabetic rats with delayed gastric emptying by redu-
cing oxidative stress and inhibiting NF-κB activation, in-
creasing SCF/Kit expression, and normalizing the delay
in gastric emptying.
Materials and methods
Experimental rats and induction of diabetes
Male SD rats (8 weeks of age) were bred in the Center
of Experimental Animals, Zhejiang Chinese Medical
University, (Hangzhou, China), where a specific pathogen-
free (SPF)-level laboratory has been authorized by the
Zhejiang provincial government. All rats were housed
under conditions of controlled humidity (50–60%). They
were maintained under controlled light (12 h day/night
cycle) with free access to water and rodent chow. All ani-
mal experiments were performed in consistency with the
license from the Zhejiang Province Science and Technol-
ogy Office (Hangzhou, China) and with approval from the
animal ethics committee of Zhejiang Chinese Medical
University. All experiments conformed to guidelines for
ethical conduct in the care and use of animals. Every effort
was made to minimize stress to the animals.
Rats fasted for 12 h were subjected to a single
intraperitoneal injection of streptozotocin (STZ), 50 mg/
kg, freshly dissolved in 100 mM sodium citrate buffer at
pH 4.5. Age-matched normal rats received citrate buffer
only. Development of diabetes was confirmed by fasting
blood glucose (FBG) levels using a reagent kit (Roche,
Shanghai, China). Rats with FBG levels higher than
11.1 mM (200 mg/dl) at 72 h after STZ injection were
considered to be diabetic rats. Once the rats became
diabetic, their glucose levels were measured daily.
Experiments commenced 8 weeks after the development
of diabetes to allow gastroparesis to develop.
Experimental design
Eight weeks after the development of diabetes, animals
were divided into four groups, i.e. normal control male
rats (Group I), diabetic male rats (Group II), curcumin-
supplemented diabetic male rats (Group III), and
curcumin-supplemented control male rats (Group IV).
Rats in groups III and IV (n = 10 each) were treated
daily with curcumin (150 mg/kg; i.g.) for 6 weeks.
Curcumin (purity > 95%) from Fusong County Natural
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pended in 0.5% w/v sodium carboxymethyl-cellulose
(CMC-Na) solution. Rats in groups I and II (n = 10
each) received 0.5% CMC-Na solution only. After treat-
ment for 6 weeks, the animals were sacrificed under
ethyl ether anesthesia, blood was collected by femoral
vein bleeding and serum was separated. Stomachs were
rapidly removed, and tissue samples collected from
animals were stored at −80°C until processed for bio-
chemical assays. Gastric emptying, oxidative stress, NF-
κB activation, ICCs and SCF/Kit expression in stomachs
were also studied at the end of the sixth week of treat-
ment (14th week of diabetes).
Gastric emptying studies
The standard method for preparing a phenol red marker
meal was employed as described previously [17]. Gastric
emptying was determined using a modification of a previ-
ously reported procedure [18]. Rats were allowed free ac-
cess to water until 3 h before gavage administration of
curcumin. A solution of 0.1% (w/v) phenol red in aqueous
sodium carboxymethylcellulose (1.5% w/v) was used as a
test meal. Curcumin was given 1 h before the oral admin-
istration of the test meal. Twenty minutes after the admin-
istration of the test meal, the rats were sacrificed. The
stomachs were then exposed by laparotomy and removed.
Rats treated with the vehicle (saline, 0.9% sodium chloride
solution, 0.2 mL) were sacrificed immediately after oral
administration of the test meal and the phenol red content
in the stomach was considered as the standard (100%).
The removed stomachs were incised in 40 mL of NaOH
solution (0.1 N) and the contents were dissolved. A 1-mL
aliquot of the washing solutions was added to 2 mL of
trichloroacetic acid (7.5% w/v) to precipitate proteins.
After centrifugation (2500 × g) for 20 min, 1 ml of the
supernatant was added to 1 ml of NaOH (1 N) to develop
the maximum intensity of color. The absorbance at
558 nm of the solution was then measured using a
spectrophotometer (U-1080; Hitachi Ltd., Tokyo, Japan).
Gastric emptying was calculated according to the fol-
lowing formula:
Gastric emptying %ð Þ ¼ 1–X=Yð Þ  100;
where X is the absorbance of phenol red remaining in the
stomach 20 min after phenol red administration and Y is
the mean absorbance of phenol red recovered from the
stomachs of control mice immediately after phenol red
administration.
Determination of MDA and SOD levels in smooth muscle
of gastric antrum
The stomachs were excised, weighed, and immediately
frozen at −70°C. Frozen tissue from each rat washomogenized in ice-cold phosphate buffer (KCl 140 mM,
phosphate 20 mM, pH 7.4) and centrifuged at 3000 × g for
10 min. The content of malonaldehyde (MDA), an in-
dex for lipid peroxidation, was determined using the
thiobarbituric acid (TBA) method with slight modification
[19]. Briefly, 100 μl of tissue homogenate was mixed with
200 μl of work solution containing 0.37% TBA. The mix-
ture was incubated at 100°C for 15 min and subsequently
cooled. To extract MDA, 375 μl of N-butanol was added,
followed by vortexing vigorously for 10 s. After centrifuga-
tion, the upper N-butanol layer was transferred to a glass
tube. The absorbance of the butanol phase was measured
at 532 nm. MDA content is expressed as nmol/mg pro-
tein. For measurement of SOD activity, 20 μl of tissue
homogenate was mixed with 200 μl of reaction solution
containing nitroblue tetrazolium chloride (NBT, 750 μM),
and incubated for 20 min at 37°C. The absorbance at
560 nm was measured. Enzyme activity is expressed as
units/g protein and 1 unit of enzyme was defined as the
amount of enzyme required to inhibit the reduction of
NBT by 50%.
Semiquantitative RT-PCR measurement of SCF and c-kit
The proximal stomach (40–50 mg) was harvested, and
the mucosa was removed by dissection. The tissue was
mechanically homogenized under RNase-free conditions
and dissociated with Tripure isolation reagent (Roche,
Switzerland) on ice for 5 minutes, and total RNA was
extracted according to the manufacturer’s instructions.
Total RNA was quantified spectrophotometrically at 260
and 280 nm, with the A260/A280 ratio ranging from 1.8
to 2.0. RNA integrity was verified by agarose gel electro-
phoresis, followed by ethidium bromide staining, and
RNA was used for immediate reverse transcription or
stored at −80°C in RNase-free water. Two-step reverse
transcriptase-polymerase chain reaction (RT-PCR) was
performed using the Revertra ace-α- first strand cDNA
synthesis kit (Tiangen Biotech, Beijing, China) and 2 ×
Taq PCR master mix (Tiangen Biotech), according to
the manufacturer’s instructions. A fixed amount of RNA
(0.5 μg) was reverse transcribed. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was selected as an in-
ternal standard. All PCR primers were designed and
synthesized by Biosune (Shanghai, China). The primer
sequences and lengths of the PCR products are as
follows: GAPDH, forward: 50-GACAACTITG-GCATC
GTGGA-30, reverse: 50-ATGCAGGGATGATGT-TCTG
G-30, 150 bp; SCF, forward: 50-GGA CTT CAT GGT
GGC ATC TG-30, reverse: 50-GCC CTT GTA AGA
CTT GAC TG-30, 285 bp; and c-kit, forward: 50-GTG
GTT AAA GGA AAC GCT CG-30, reverse: 50-CAT
ACA TTT CAG CAG GTG CG-30, 400 bp. Reaction
conditions were optimized for each of the genes by vary-
ing the annealing temperature (58°C for GAPDH, 58°C
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PCR cycles [20]. The PCR products were separated on
2% agarose gels at 100 V for 30 minutes. Gel images
were displayed on the liquid crystal display monitor of
an ultraviolet transillumination PhotoDoc-Ite system
equipped with a CCD camera (Bio-Rad Gel Doc 2000,
Bio-Rad Laboratories, Hercules, CA) and preserved for
intensity analysis. The relative mRNA levels of the
selected genes were calculated as the ratio to GAPDH
expression.
Levels of SCF, c-Kit, IκB and NF-κB assessed by western
blot analysis
About 50 mg of tissue was taken from the near proximal
stomach. Tissues were cut into little pieces of about
0.25 cm3, homogenized, and dissociated in radio-
immunoprecipitation assay lysis buffer (Hushang Bio-
technology, Shanghai, China), containing 50 mM tris,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
1% sodium dodecyl sulfate, 1 mM PMSF, sodium
orthovanadate, sodium fluoride, ethylenediaminetetra-
acetic acid, and leupeptin at 4°C for 30 minutes.
Homogenates were centrifuged at 12 000 × g for 5 -
minutes at 4°C, and the supernatants were collected and
used as total protein. Equal amounts of protein were
electrophoresed by SDS-PAGE in 10% or 15% polyacryl-
amide gels. Proteins were transferred onto nitrocellu-
lose membranes (Hushang Biotechnology) by semidry
blotting. Membranes were blocked with Tris-buffered
saline 0.1% Tween 20 (TBST) containing 5% milk for
60 minutes at room temperature, and then immuno-
blotted with appropriately diluted primary antibodies at
4°C overnight. After washing three times with TBST, the
blots were incubated with HRP-conjugated secondary
antibody for 60 minutes at room temperature. Then, the
complexes were visualized using an iChemi XR imaging
system (WD9431A, Bomeike Biotechnology, China)
with chemiluminescence reagents (Tigsun Biological Sci-
ence Technology, Tianjin, China). Semi-quantification was
performed using Quantity One software, version 4.6.2
(Bio-Rad). The following antibodies were used: anti-SCF,
1:200, c-kit, 1:200, anti-IκB and anti-NF-κB p65 and
GAPDH, 1:500 (Hushang Biotechnology, Shanghai, China).
Quantification of NF-κB -DNA binding by electrophoretic
mobility shift assay
Nuclear extracts were prepared from stomach lysates as
described previously [21]. NF-κB activation was de-
termined by an electrophoretic mobility shift assay
(EMSA), and nuclear translocation of NF-κB was
assessed as described previously (GS009, Beyotime Insti-
tute of Biotechnology, Shanghai, China) [22]. For NF-κB
binding reactions, 5 μg of nuclear protein extract was
incubated at room temperature for 20 min with reactionbuffer containing 20 mM HEPES, pH 7.9, 50 mM KCl,
0.1 mM EDTA, 1 mM DTT, 5% glycerol, 200 μg/mL
BSA, and 2 μg of poly (dI-dC). Then, 32P-labeled
double-stranded oligonucleotide (1 ng ≥1×105 cpm)
containing the NF-κB binding consensus sequence (50-
GGCAACCTGGGGACTCTCCCTTT-30) was added to
the reaction mixture for an additional 10 min at room
temperature. The reaction products were fractionated on
a non-denaturing 6% polyacrylamide gel for 60 min at
350 V, which was then dried and subjected to autoradi-
ography at −70°C overnight. For competition assays, ex-
cess oligonucleotide (100-fold molar excess) competitor
was pre-incubated with nuclear extracts for 20 min at
room temperature. A mutant NF-κB oligonucleotide (50-
GGCAACTGCTCACTCTCCCTTT-30) was used for
the competition assay. Signals were densitometrically
analyzed.
Double immunofluorohistochemistry with terminal
deoxynucleotidyl transferase-mediated dUTP-biotin nick
end labeling assay (TUNEL) and c-kit staining
Fluorescence immunohistochemistry for c-kit (using the
antibody from Santa Cruz) and TUNEL staining were
performed on 10-μm sections using a modification of
the procedure published by the manufacturer of the
TUNEL kit (TACS sTdT, Trevigen Inc, Gaithersburg,
MD). TUNEL-positive cells were labeled with fluores-
cein (Ex 488, Em 505–550), c-kit-positive cells were la-
beled with Cy3 (Ex 543, Em 560–615), and nuclei were
labeled with DAPI (Ex 364, Em 385–470). Tissue
specimens were embedded in fluorescence mounting
medium and investigated by confocal laser scanning mi-
croscopy [23]. Approximately 200 cells were counted per
field, five fields were examined per slide and five slides
were examined per group. The percentages of TUNEL-
and c-kit-positive apoptotic cells were denoted as the
apoptotic index (AI) (%).
Statistical analysis
All data are presented as means ± SD. To compare data
among groups of animals, one-way analysis of variance
(one-way ANOVA) and Duncan comparisons were
employed. All statistical tests were performed using
SPSS for Windows, version 13.0 (SPSS Inc, Chicago,
IL). Differences were considered statistically significant
at P < 0.05.
Results
Effect of curcumin on body weight and blood glucose of
diabetic rats
Plasma glucose levels were highly elevated in diabetic
rats (Group II) [(322 ± 41) mg/dl] compared with those
in normal control rats (Group I) [(98 ± 12) mg/dl].
There was a marked decline in the body weights of
Figure 1 Effects of curcumin on gastric emptying in diabetic
rats. Group I=normal control rats (n=10); : Group II=diabetic
control rats (n=10); : Group III=diabetic + curcumin treated rats
(n=10); : Group IV=normal + curcumin treated rats (n=10). All values
are expressed as the mean ± SD. *p<0.01 (compared to Group I),
# p <0.05 (compared to Group II), Δp >0.05 (compared to Group I).
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Group I rats [(449 ± 21) g]. Chronic curcumin-treated
diabetic rats (Group III) showed no significant im-
provements in body weight and no decline in plasma
glucose levels compared with Group II rats [Group III,
body weight (324 ± 19) g and glucose (302 ± 38) mg/dl]
(Table 1).
Effect of curcumin on gastric emptying
Gastric emptying was significantly delayed in SD rats
that had had diabetes for 8 weeks. The amount of gastric
emptying in Group II was 44.3 ± 5.7%, which was sig-
nificantly lower than that in Group I [(76.2 ± 4.3)%,
P < 0.01], and diabetic rats undergoing curcumin treat-
ment [(Group III),; (59.4 ± 7.5)%, P < 0.05]. However, no
significant difference was noted between Group I and
Group IV rats [(73.3 ± 5.2%), P > 0.05] (Figure 1).
Curcumin treatment decreased MDA formation, increases
SOD activity
We investigated oxidative stress using several methods
because glucose-induced oxidative stress has been
postulated to be a key mechanism in chronic diabetic
complications. Diabetic rats exhibited increased MDA
levels [Group I 15.7 ± 1.7 (nmol/mg) vs Group II 27.9 ±
2.1 (nmol/mg), P = 0.006] and decreased SOD levels
[Group I 146.2 ± 9.3 (u/mg) vs Group II 107.9 ± 7.5
(u/mg), P = 0.008], a molecular marker of oxidative
stress (Figure 2). Six weeks of curcumin treatment
reduced the degree of MDA upregulation [Group III,
21.4 ± 1.8 (nmol/mg), P = 0.033 versus Group I and
P = 0.004 versus Group II], and improved the SOD
down-regulation [Group III 126.2 ± 8.8 (units/mg),
P = 0.036 versus Group I and P = 0.001 versus Group
II]. Curcumin significantly enhanced SOD activity and
reduced MDA levels in stomach homogenates. Further-
more, no significant difference were noted between
Group I and Group IV animals (P > 0.05; Figure 2).
Curcumin increases SCF and c-kit protein levels
Representative images of the RT-PCR analysis of SCF in
the stomach tissues of rats in each group are shown in
Figure 3A. Compared with Group I, the SCF was signifi-
cantly lower in Group II [(0.44 ± 0.02) vs (0.69 ± 0.03),Table 1 Blood glucose level and body weight in four
groups
Groups Group I Group II Group III Group IV
Blood glucose(mg/dl) 98±12 322±41* 302±38*# 100±11
Body weight(g) 449±21 298±16* 324±19* 476±27
Group I=normal control rats; Group II=diabetic control rats; Group III=
diabetic + curcumin treated rats (150 mg/kg); Group IV=normal + curcumin
treated rats (150 mg/kg). Results are presented as mean ± SD. *P < 0.05
(compared to Group I), # P >0.05 (compared to Group II).P = 0 .002], and a comparison of the values in Group III
revealed that the SCF level in curcumin-treated rats was
greater than that in Group II [(0.58 ± 0.04) vs (0.44 ±
0.03) P = 0 .003]. However, no differences were noted
between Groups I and IV [(0.69 ± 0.03) vs (0.66 ± 0.03)
P = 0.56] (Figure 3B). Western blot analysis (Figure 4A,
B) revealed that the level of SCF in stomach tissues from
Group II rats was significantly lower than those in
Group I and III rats [ratios of (0.33 ± 0.02) vs (0.47 ±
0.03) and (0.41 ± 0.02), respectively, P < 0 .05)]. How-
ever, no significant difference was found between Group
IV and Group I rats [(0.45 ± 0.03) vs (0.47 ± 0.03),
P > 0.05)], suggesting that curcumin intervention could
effectively restore local SCF protein levels in the stom-
ach tissues of diabetic rats.
RT-PCR analysis showed that the expression levels for
c-kit in stomach tissues were 0.78 ± 0.04, 0.37 ± 0.02,
and 0.59 ± 0.03 for Groups I, II and III, respectively. The
c-kit expression levels in Groups II and III rats were
lower than that in Group I rats. However, a comparison
of Groups II and III revealed that the c-kit level in
curcumin-treated rats was greater than that in non-
treated diabetic rats (P < 0.05, Figure 3B). Similar
outcomes were demonstrated by western blot analysis
(Figure 4B). The levels of c-kit protein (ratios of 0.45 ±
0.03, 0.21 ± 0.02 and 0.34 ± 0.02, respectively, for
Groups I, II and III) were much greater in Group III
than in Group II (P < 0 .05, Figure 4B), and the level in
Group III was lower than those in Groups I and IV. Both
analyses indicated that 6 weeks of curcumin intervention
could significantly restore the decrease in c-kit levels in
diabetic rats.
Figure 2 Effects of curcumin on MDA and SOD in diabetic rats.
The levels of MDA was decreased after treated with curcumin, the
levels of SOD was increased after treated with curcumin. : Group
I=normal control rats (n=10); : Group II=diabetic control rats (n=10);
Group III=diabetic + curcumin treated rats (n=10); : Group IV=
normal + curcumin treated rats (n=10). All values are expressed as
the mean ± SD.*p<0.01 ( compared to Group I), # p <0.01
(compared to Group II), Δp >0.05 (compared to Group I).
Figure 3 Changes in SCF/GAPDH and C-kit/GAPDH by RT-PCR
analysis. (A) Representative images of gel electrophoresis of
GAPDH,SCF, and c-kit in rats of each group. (B) Group levels of
relative mRNA expression of SCF and c-kit, with products quantified
by ratio to GAPDH. : Group I=normal control rats (n=10); : Group
II=diabetic control rats (n=10); : Group III=diabetic + curcumin
treated rats (n=10); : Group IV=normal + curcumin treated rats
(n=10). All values are expressed as the mean ± SD. *p<0.01
(compared to Group I.), # p <0.05 (compared to Group II), Δp >0.05
(compared to Group I).
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Reports indicate that increased and chronic oxidative
stress can activate or perturb NF-κB activity [24]. We
investigated whether curcumin could result in activation
of the NF-κB signaling pathway. To do this, we
measured the levels of NF-κB in the presence or absence
of curcumin to identify whether NF-κB was activated.
First, we evaluated the protein levels of I-κB, to which
inactivated NF-κB binds. We found that the level of I-κB
in Group I rats was higher than that in Group II rats,
while the level in Group III rats was lower than that in
Group II rats (p < 0.01), but higher than the levels in
Figure 4 Changes in SCF/GAPDH and C-kit/GAPDH by Western
blot analysis. (A) Representative protein band images of SCF, c-kit,
and glyceraldehydes-3-phosphate dehydrogenase (GAPDH).
(B) Group levels of relative SCF and c-kit protein expressed by ratio
to GAPDH,respectively. : Group I=normal control rats (n=10); : Group
II=diabetic control rats (n=10); : Group III=diabetic + curcumin
treated rats (n=10); : Group IV=normal + curcumin treated rats
(n=10). All values are expressed as the mean ± SD. *p<0.01
(compared to Group I), # p <0.01 (compared to Group II),
Δp >0.05 (compared to Group I).
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whether curcumin could block NF-κB. We found that
diabetes (Group II) led to an increase in NF-κB levels
[Group I 75.5 ± 7.7 (pg/ml) vs Group II 102.8 ± 12.4
(pg/ml), P = 0.001], while treatment with curcumin
[Group III 91.3 ± 8.9 (pg/ml)] prevented this effect.
Based on this finding, we suggested that curcumin
suppresses activation of NF-κB [Group IV 70.9 ± 8.1
(pg/ml), P = 0.026] (Figure 5). We examined whether
curcumin could block NF-κB translocation into the nu-
cleus, because nuclear translocation is recognized as a
cell reaction to ROS stimulation and seems to correlate
with NF-κB-mediated transcriptional activation. To as-
sess this, we measured the level of NF-κB in the nucleus
by EMSA. Development of diabetes induced an increase
in NF-κB levels in the nucleus, while treatment with
curcumin prevented this effect (Figure 6). Thus, we
suggested that curcumin not only indirectly suppresses
activation of NF-κB–DNA binding, but that it also
suppresses activation upstream of I-κB.
Curcumin reduces apoptosis of ICCs and promotes their
proliferation in stomach tissues
To further analyze the chemopreventive action of
curcumin on diabetic gastroparesis, we examined its ef-
fect on apoptosis in diabetic stomach sections by double
immunofluorohistochemistry. Figure 7 shows represen-
tative images of apoptosis in stomach tissue sections
from rats of all four groups. The chromogen-generated
yellow stain is an indication of apoptotic ICCs. It should
be noted that in almost every case the yellow stain
overlaps the condensed chromatin of apoptotic bodies,
thus confirming that the results of the double immu-
nofluorohistochemistry assay correlate well with the
morphological appearance of apoptosis. The rate of
apoptosis was generally very low in Group I rats. Typic-
ally, in sections from diabetic rats, we found an average
of 80–100 apoptotic cells in a field of about 200 cells.
This number decreased to 40–50 stained cells in the
curcumin-treated rats. As seen in Table 2, the propor-
tion of apoptotic ICCs in the stomachs [AI:(47.5 ±
6.2)%] of Group II rats was markedly higher than that in
the stomachs of Group I rats [AI:(6.4 ± 1.8)%]. This
effect of diabetes was mostly reversed by curcumin
[(26.2 ± 4.1)% for Group III], with a difference that was
statistically significant (P < 0.05). However, no significant
difference in AI was noted between Group I and IV rats
[AI for Group IV: (7.1 ± 2.4)%] (P > 0.05).
Discussion
Numerous recent studies have demonstrated the ability
of curcumin to halt or prevent certain types of cancer,
decrease inflammation, and improve cardiovascular
health. However, very few studies have examined its
Figure 5 Effect of curcumin on I-κB and NF-κB. (A) the bar graph
was clear reflection of the level of I-κB and NF-κB among four
groups. (B) the level of I-κB/GAPDH was decreased in Group II,but
increased by curcumin. I: Group I=normal control rats (n=10); II:
Group II=diabetic control rats (n=10); III: Group III=diabetic +
curcumin treated rats (n=10); IV: Group IV=normal + curcumin
treated rats (n=10). All values are expressed as the mean ± SD.
*p<0.01 (compared to Group I), # p <0.01 (compared to Group II),
Δp >0.05 (compared to Group I).
Figure 6 Effect of curcumin on NF-κB activation. Nuclear extracts
were prepared and assayed for NF-κB -DNA binding activation by
EMSA. The graph was clear reflection of the NF-κB -DNA binding
activation among four groups. the level of NF-κB was increased in
Group,but decreased by curcumin. Bars represent the mean ± SD
from four different groups. : Group I=normal control rats (n=10); :
Group II=diabetic control rats (n=10); : Group III=diabetic +
curcumin treated rats (n=10); : Group IV=normal + curcumin treated
rats (n=10). All values are expressed as the mean ± SD. *p<0.01
(compared to Group I), # p <0.01 (compared to Group II), Δp >0.05
(compared to Group I).
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study, we demonstrated that supplementation with
curcumin attenuated oxidative stress and NF-κB activa-
tion, and prevented the down-regulation of SCF/c-kit
protein level in diabetic rats. Our result suggests thatthe increased gastric dysfunction in diabetic rats can be
prevented by curcumin treatment.
Data presented in this study show that SCF/c-kit is
down-regulated after the development of diabetes and
the concurrent increase in the level of oxidative stress.
This down-regulation of SCF/c-kit was lost in all rats
that went on to develop delayed gastric emptying and
maintained in all rats that did not develop delayed gas-
tric emptying. Failure to maintain down-regulation of
SCF/c-kit and develop delayed gastric emptying was
associated in all rats with high levels of markers of oxi-
dative stress and NF-κB. In the curcumin-treated rats,
ICCs were protected, suggesting that the maintenance
of normal gastric function requires decreased ROS,
Figure 7 Double Immunofluorohistochemistry With TUNEL and c-Kit in stomach tissues(×400 times). A: Group I=normal control rats;
B. Group IV=normal + curcumin treated rats C. Group III=diabetic + curcumin treated rats. D. Group II=diabetic control rats; Representative
images of TUNEL positive and c-kit positive ICC from sections of stomach tissues of diabetic rats.Red were c-kit positive cells in tissues. Green
were apoptotic cells in tissues.Yellow were TUNEL positive and c-kit positive apoptotoc ICCs.Numbers of TUNEL positive and c-kit positive
apoptotic ICCs(yellow stain)expressed as the % of total number of ICCs in the circular muscle layer of each section. Yellow-stained ICCs are
undergoing apoptosis.
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pression (e.g. restored to normal levels).
Diabetes is a pathologic condition, and the morbidity
and mortality associated with diabetes are the result of
myriad complications related to the disease. Oxidative
stress plays an important role in the etiology of the dis-
ease, and is considered to be the main factor leading to
the development of diabetic complications and tissue in-
jury [25]. Diabetes is associated with increased oxidative
stress [26]. Oxidative stress mediates many of the dele-
terious effects of diabetes on organ function, and indu-
ces not only gastric mucosal injury, but also gastric
motility dysfunction, such as diabetic gastroparesis [7].
Gastroparesis is thought to be caused by ROS-induced
damage to the networks formed by ICCs [27]. Moreover,Table 2 Apoptotic value of ICCs in stomach tissue






Group I=normal control rats; Group II=diabetic control rats; Group III=
diabetic +curcumin treated rats (150 mg/kg); Group IV=normal + curcumin
treated rats (150 mg/kg).* P<0.001, significant difference compared to Group
II; # P<0.01, significant difference Compared to Group II. Δ P<0.05 significant
difference compared to Group I and Group IV.antioxidants can reverse diabetic gastroparesis in NOD
mice [6]. ICCs in normal tissues are resistant to oxida-
tive stress caused, for example, by hyperglycemia [28],
but they can become vulnerable to glycemic stress when
antioxidant defenses are compromised [6]. The results of
our study show the potential mechanisms by which oxi-
dative stress induces gastric motility dysfunction in
diabetic rats. Diabetic rats exhibited slower gastric
emptying together with increased MDA levels and
decreased SOD levels compared with normal rats, with a
tight correlation between high levels of MDA and the
presence of delayed gastric emptying. Why does oxida-
tive stress damage stomach function? ROS might inflict
direct damage to vital cell constituents such as lipids,
proteins and DNA, but also modulate patterns of gene
expression through functional alterations of transcrip-
tion factors such as NF-κB [29]. First, mature ICCs are
easily damaged under conditions of oxidative stress [6].
ROS are a crucial regulator of cellular signal transduc-
tion and energy transmission, and a disturbance of the
balance between ROS-generating and ROS-scavenging
capabilities might lead to cell damage. Oxidative stress is
now recognized as a stimulator of cell responses such as
apoptosis [30]. A growing number of studies have
described that ROS can activate inflammasomes in cells,
leading to increased production of TNF-α, IL-1, IL-6
and IL-18 [31]. All sorts of inflammatory factors may
directly damage ICCs. We examined the effect of
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finding that ROS content was significantly greater in
Group II animals than in Group III animals suggests that
curcumin attenuates diabetes-induced ROS formation.
Our results also revealed that curcumin is a potent in-
hibitor of ROS-induced apoptosis. NF-κB is known to be
a key factor in up-regulating inflammatory cytokines.
NF-κB activation enhances the transcription of pro-
inflammatory cytokines, and these cytokines in turn acti-
vate NF-κB [14]. A perturbation of NF-κB distribution
promoted inflammatory mediator-mediated ICC apop-
tosis. NF-κB is normally located in cytoplasm where it
binds I-κB to form an inactive complex. The phosphor-
ylation and subsequent degradation of I-κB result in NF-
κB activation. We found that the NF-κB level in the
cytoplasm was higher in diabetic rats than in control
rats. Activated NF-κB migrates into the nucleus, and
causes the expression of inflammatory cytokines. A com-
parison of the nuclear NF-κB levels in Group II and III
rats revealed that nuclear localization of NF-κB is mark-
edly inhibited by curcumin. We also found that I-κB is
degraded in the stomach smooth muscle of diabetic rats.
Activation of NF-κB was induced by phosphorylation of
the inhibitor IkB, in response to diverse stimuli includ-
ing ROS, which leads to its degradation and results in
unmasking of nuclear localization signals that allow NF-
κB to be translocated into the cell nucleus [32]. ROS can
directly activate NF-κB by degrading or modifying I-κB
in the cytoplasmic NF-κB–IκB complex [33]. The results
of this study show that, in rats with experimentally
induced gastroparesis, proteolysis of IκB results in acti-
vation and nuclear translocation of NF-κB, and that this
was accompanied by ROS up-regulation. Previously,
various authors have reported that curcumin is a potent
inhibitor of transcription factors [34,35], and that the
suppression of NF-κB activation by curcumin results, in
turn, in a down-regulation of ROS and inflammation [36].
It was suggested that loss of ICCs might have a major
role in the pathogenesis of diabetic gastroparesis [37],
and that the degree of ICC loss was in proportion to the
severity of symptoms or changes in gastric emptying.
Curcumin neutralized diabetes-induced oxidative stress,
reduced MDA levels, improved SOD levels, restored
NF-κB activity, and inhibited inflammatory mediator
production, thereby minimizing diabetes-induced ICC
apoptosis. All of these observations point toward a
crosstalk between a ROS–NF-κB–inflammation me-
diator in deciding the fate of ICC cells in a high glu-
cose micro-environment, and the intervening role of
curcumin.
Reduced SCF levels in the stomachs of diabetic mice
have been reported [38]. Because SCF/c-Kit signaling is
important for the maintenance of ICC phenotypes,
proliferation, and differentiation [25], we investigatedwhether ICCs could regenerate after impairment in dia-
betic rats following curcumin treatment. Furthermore,
the kit ligand SCF was mainly observed in the smooth
muscle cells (SMCs), which are located close to ICCs. In
the proximal stomach, intramuscular ICC rather than
myenteric ICC are the main subtypes of ICCs that give
rise to gastric slow waves and act as the dominant pace-
maker cells. Previous studies have shown that SCF is im-
portant for maintaining a steady level of ICCs in
stomach tissues. SCF is produced by SMCs in the long-
term maintenance of ICCs, while ICC depletion in dia-
betes is accompanied by smooth-muscle atrophy and
reduced SCF levels [39]. Exogenous SCF can partially re-
verse the pathological changes in ICCs in diabetic mice,
because SCF is necessary for differentiation of pre-
cursors into ICCs [38]. In our study, we found the SCF/
c-kit levels and ICC numbers were clearly declined in
diabetic gastroparesis rats compared with control rats.
Indeed, the loss of SCF might be responsible for the loss
of ICCs. The levels of mRNA expression for SCF and c-
kit were lower in the stomach tissues of diabetic rats
than non-diabetic rats, and decrease was significantly
reversed by the curcumin intervention. These findings
showed that curcumin improves SCF/c-kit levels in the
stomach tissues of diabetic rats. These results also indi-
cate that the fate of ICCs in diabetes depends on SCF/c-
kit from SMCs, but probably not that from myenteric
neurons [38]. No differences in fasting blood glucose
levels and body weight were noted before and after treat-
ment in the same groups of rats, indicating that the
pathologic ICCs changes can be attributed to a defi-
ciency of endogenous SCF/c-kit, and not related to
hyperglycemia. We showed that ICC loss owing to dia-
betes involves reduced expression of SCF/c-kit and a
critical differentiation and survival factor for ICCs. De-
velopmental studies have demonstrated that c-kit+ mes-
enchymal precursor cells appear to generate ICCs and
the longitudinal muscle layer [39]. Cell fate decisions be-
tween becoming an ICC or a SMC depend on SCF/c-kit
signaling. We found that a loss or lack of SCF and c-kit
ligand could lead to the apoptosis of ICCs, but when
Group II rats were treated with curcumin, we observed
an increase in SCF/c-kit concentration in the micro-
environment promoting ICC transdifferentiation back
into a normal phenotype. Our results suggest that
curcumin could aid in the restoration of the SCF/c-kit
signaling pathway, which is essential for ICC phenotype
restoration and functional recovery. These results
reinforce the results of previous studies showing that
ICCs displaying distinctive plasticity can be controlled
by changing the level of SCF/c-kit signaling.
Overall, our results show that curcumin has an effect
on anti-oxidation and free radical removal. We further
show that curcumin reduces activation of NF-κB via
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suggest that curcumin promotes the expression of SCF/
c-kit. As a result, we have a better understanding of the
molecular mechanism by which curcumin protects ICCs,
namely, via blocking of oxidative stress, inhibition of
NF-κB activation and an enhancement of SCF/c-kit
expression.
Conclusion
We suggest that curcumin can have a remarkable pro-
tective effect on ICCs and a therapeutic effect on gastric
emptying dysfunction in diabetic rats.
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